First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
about
Inflammatory bowel disease as a model for translating the microbiomeCost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximabPrognostic biomarkers to identify patients destined to develop severe Crohn's disease who may benefit from early biological therapy: protocol for a systematic review, meta-analysis and external validation.A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease.Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.Interleukin-18: Biological properties and role in disease pathogenesis.Optimization of biologic therapy in Crohn's disease.Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target.A MAPP Network Study: Overexpression of Tumor Necrosis Factor-α in Mouse Urothelium Mimics Interstitial Cystitis.Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease.Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel
P2860
Q26853123-116F0C18-10FE-4CFB-B05C-301FEA81D3B8Q36714704-E3933293-3BCA-4CAF-B034-9A6A5C2A22BAQ37460415-FBAB74BC-FCA9-4E6E-A4B7-25C432749B41Q37678199-A5AE41AA-642E-426D-BB66-15BAC272A6F4Q38365049-C4E49BB0-0F79-4CF8-A05C-7FF58EE8404EQ38549995-C3483DC9-F288-491E-9D04-AF9AF1294731Q38726458-D627F374-8DC9-416C-86DF-DB14C2E1939FQ38752119-E3F54762-775A-4628-962A-53893CBA7A97Q38850063-CE01F1EA-8C42-466C-AF29-9E77DE8669A0Q38963689-8B7BCE6C-3D47-4954-AC51-86810D7BE6DCQ47285927-CB33914B-EA2A-41C6-AC21-B0C5AC9034F3Q47389870-D5EBFDF6-1A6D-46AC-820B-DB75083061EAQ48218369-435719CD-C3B9-445E-ACE6-20DDA989734CQ48518781-6745EF82-90F3-4633-A004-B99A523A6C18Q49714265-BF99C1D8-2AEC-41CF-9796-EE4D04E3C322Q52430882-0304D139-C33C-43CC-A435-E3B6F06D7FC4Q58707775-7B66BF69-23B4-4FB1-8EEF-BF0DF1998BAB
P2860
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
@en
type
label
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
@en
prefLabel
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
@en
P2860
P921
P356
P1476
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
@en
P2093
Anthony Buisson
Silvio Danese
P2860
P2888
P304
P356
10.1038/NRGASTRO.2013.31
P407
P577
2013-03-05T00:00:00Z